Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. (XERS), a biopharmaceutical company, filed this Form 8-K on January 8, 2026. The report announces preliminary financial results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
The filing does not disclose specific material changes versus prior periods. It serves solely as a notification that preliminary results for the fourth quarter and full year 2025 have been issued.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It explicitly states that the information in the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual numerical results for Q4 and full-year 2025.
- Verify the company's cash position and runway given the lack of disclosed liquidity metrics in this summary.
- Confirm if the preliminary results include any updates to clinical trial timelines or regulatory milestones.
- Check for any subsequent filings that may incorporate the press release data by reference.